Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Insulin Versus Topical Irradiated Amniotic Fluid Gel for Treatment of Epidermolysis Bullosa
NCT07907523Completed
- Sponsor
- Tanta University
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Open-label trial of Generex Oral-lyn in epidermolysis bullosa (EB) (3 arms), sponsored by Tanta University. Primary endpoint: Change in wound surface area at 9 weeks. Started Jan 2025; status: completed.
02
Drugs
Generex Oral-lyn
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT07907523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07907523.